Wei et al. demonstrated that sorafenib, a multi-kinase inhibitor employed in hepatocarcinoma and in relapsed FLT3-ITD acute myeloid leukemia, not only inhibits ABCG2 efflux activity but induces ABCG2 degradation in the lysosome [169]. This evidence concerns the gene FLT3 and acute myeloid leukemia.